Document Type : Original Article(s)


1 Psychiatrist, Department of Psychiatry, Clinical Research Development Unit, 22 Bahman Hospital, Qazvin University of Medical Sciences, Qazvin, Iran

2 Assistant Professor, Department of Psychiatry, Clinical Research Development Unit, 22 Bahman Hospital, Qazvin University of Medical Sciences, Qazvin, Iran

3 Assistant Professor, Department of Psychiatry, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran

4 PhD, Children Growth Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran


BACKGROUND: Some types of antidepressants and antipsychotic medications have cardiovascular side effects that can be life-threatening. Electroconvulsive therapy (ECT) is capable of generating physiological stress and may lead to increased QT interval followed by arrhythmias. Risperidone can also increase the risk of arrhythmia by increasing the corrected QT (QTc) interval. Since many patients require co-administration of risperidone and ECT, this study aimed to investigate the concurrent effect of ECT and risperidone administration on the QTc interval.METHODS: For this cross-sectional study, 60 patients (18-65 years) admitted in 22 Bahman Psychiatric Hospital (Qazvin, Iran) that were candidate for treatment with risperidone, ECT, or both methods were concurrently divided into three groups. The groups included patients treated with ECT, risperidone, and combination treatment (risperidone and ECT). At the beginning of the study, electrocardiogram (ECG) was obtained for all patients and QT was performed manually, and finally, QTc interval was measured two times for each group. Required information was collected through medical records. Then, inferential statistics, analysis of variance (ANOVA), was used to determine differences between different variables.RESULTS: A significant increase in heart rate (HR) in the third group compared to first and second groups was observed. None of the treatments had a significant effect on QTc interval, but the QTc interval increased slightly in groups treated with the ECT alone and particularly, the ECT plus risperidone in comparison to the baseline values.CONCLUSION: Our study showed that risperidone, ECT, and their concomitant combination did not affect the QTc interval. Therefore, risperidone and ECT are safe and their combination can also be a good option for refractory patients undergoing ECG monitoring and cardiopulmonary devices.


  1. Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 2017; 16(2): 163-80.
  2. Stoner SC. Management of serious cardiac adverse effects of antipsychotic medications. Ment Health Clin 2017; 7(6): 246-54.
  3. Mulder ME, Verwey B, van Waarde JA. Electroconvulsive therapy in a terminally ill patient: when every day of improvement counts. J ECT 2012; 28(1): 52-3.
  4. Cristancho MA, Alici Y, Augoustides JG, O'Reardon JP. Uncommon but serious complications associated with electroconvulsive therapy: recognition and management for the clinician. Curr Psychiatry Rep 2008; 10(6): 474-80.
  5. Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics 2013; 54(1): 1-13.
  6. Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J 2007; 153(6): 891-9.
  7. Sadock BJ, Sadock V. Kaplan and Sadock's synopsis of psychiatry: Behavioral. Trans. Rafiei H, Rezaei F. Tehran, Iran: Arjmand Publications; 2004. [In Persian].
  8. Weiner RD, Coffey C, Fochtmann L. The practice of electroconvulsive therapy: Recommendations for treatment, training, and privileging: A task force report of the American Psychiatric Association, 2nd ed. Arlington, VA: American Psychiatric Association; 2001.
  9. Najafi M, Tavakoli S, Ganji F, Rostami A. Effect of video education on reduction of post ETC complications. Iran J Med Educ 2011; 10(5): 1216-27. [In Persian].
  10. Nahshoni E, Aizenberg D, Strasberg B, Dorfman P, Sigler M, Imbar S, et al. QT dispersion in the surface electrocardiogram in elderly patients with major depression. J Affect Disord 2000; 60(3): 197-200.
  11. Suzuki Y, Miyajima M, Ohta K, Yoshida N, Omoya R, Fujiwara M, et al. Is prolongation of corrected QT interval associated with seizures induced by electroconvulsive therapy reduced by atropine sulfate? Pacing Clin Electrophysiol 2017; 40(11): 1246-53.
  12. Choure BK, Gosavi D, Nanotkar S. Comparative cardiovascular safety of risperidone and olanzapine, based on electrocardiographic parameters and blood pressure: A prospective open label observational study. Indian J Pharmacol 2014; 46(5): 493-7.
  13. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000; 68(1): 29-39.
  14. Rasmussen KG, Hooten WM, Dodd ML, Ryan DA. QTc dispersion on the baseline ECG predicts arrhythmias during electroconvulsive therapy. Acta Cardiol 2007; 62(4): 345-7.
  15. Erdil F, Demirbilek S, Begec Z, Ozturk E, Ersoy MO. Effects of propofol or etomidate on QT interval during electroconvulsive therapy. J ECT 2009; 25(3): 174-7.
  16. Margari L, Matera E, Craig F, Petruzzelli MG, Palmieri VO, Pastore A, et al. Tolerability and safety profile of risperidone in a sample of children and adolescents. Int Clin Psychopharmacol 2013; 28(4): 177-83.
  17. Booker PD, Whyte SD, Ladusans EJ. Long QT syndrome and anaesthesia. Br J Anaesth 2003; 90(3): 349-66.
  18. Koca E, Erdil FA, Toprak HI, Ersoy NGO, Durmus M. The effects of propofol-ketamine combination on QTc interval in patients with coronary artery disease. Med Science 2021; 10(2): 278-82.
  19. Abrich VA, Ramakrishna H, Mehta A, Mookadam F, Srivathsan K. The possible role of propofol in drug-induced torsades de pointes: A real-world single-center analysis. Int J Cardiol 2017; 232: 243-6.
  20. Kleinsasser A, Kuenszberg E, Loeckinger A, Keller C, Hoermann C, Lindner KH, et al. Sevoflurane, but not propofol, significantly prolongs the Q-T interval. Anesth Analg 2000; 90(1): 25-7.
  21. Kuenszberg E, Loeckinger A, Kleinsasser A, Lindner KH, Puehringer F, Hoermann C. Sevoflurane progressively prolongs the QT interval in unpremedicated female adults. Eur J Anaesthesiol 2000; 17(11): 662-4.
  22. Tang WK, Ungvari GS. Efficacy of electroconvulsive therapy combined with antipsychotic medication in treatment-resistant schizophrenia: a prospective, open trial. J ECT 2002; 18(2): 90-4.
  23. Painuly N, Chakrabarti S. Combined use of electroconvulsive therapy and antipsychotics in schizophrenia: The Indian evidence. A review and a meta-analysis. J ECT 2006; 22(1): 59-66.
  24. Nothdurfter C, Eser D, Schule C, Zwanzger P, Marcuse A, Noack I, et al. The influence of concomitant neuroleptic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. World J Biol Psychiatry 2006; 7(3): 162-70.
  25. Tan QR, Wang W, Wang HH, Zhang RG, Guo L, Zhang YH. Treatment of catatonic stupor with combination of modified electroconvulsive treatment and olanzapine: a case report. Clin Neuropharmacol 2006; 29(3): 154-6.
  26. Dodd ML, Dolenc TJ, Karpyak VM, Rasmussen KG. QTc dispersion in patients referred for electroconvulsive therapy. J ECT 2008; 24(2): 131-3.
  27. Wajima Z. Complication of Electroconvulsive Therapy. In: Saito S, editor. Anesthesia management for electroconvulsive therapy. New York, NY: Springer; 2016. p. 125-54.